A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) kinase domain mutations activate signaling pathways, promoting tumor growth in non-small cell lung cancer (NSCLC).
• While many EGFR mutations respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs), EGFR Exon 20 insertion (Ex20ins) mutations present a significant unmet clinical need.
• Directly targeting EGFR Ex20ins mutations is a promising therapeutic strategy for NSCLC.

Purpose of the Study:

• To review clinical studies on EGFR Ex20ins inhibitors.
• To summarize recent patents (2019-2024) related to EGFR Ex20ins inhibitors.
• To provide an overview of the current landscape and future directions in targeting EGFR Ex20ins mutations.

Main Methods:

• Literature review of clinical studies on EGFR Ex20ins inhibitors.
• Patent landscape analysis using Espacenet and CAS SciFinder databases (January 2019 - April 2024).

Main Results:

• An increasing number of EGFR Ex20ins inhibitors are under development.
• Current strategies focus on enhancing efficacy and overcoming resistance through optimized inhibitors and novel molecules.
• Emerging approaches include targeted protein degraders, allosteric inhibitors, and combination therapies.

Conclusions:

• Despite progress, challenges such as bypass resistance, selectivity, and drug sensitivity persist in targeting EGFR Ex20ins mutations.
• Continued innovation in inhibitor design and therapeutic strategies is essential.
• Addressing these challenges will improve outcomes for NSCLC patients with EGFR Ex20ins mutations.